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Although there is no doubt about its efficiency, pharma-
cotherapy of depression still faces several problems that
have to be focused upon and hopefully solved. Besides the
problem of drug-resistant depression, over the last decade
the view has become increasingly widespread that achiev-
ing remission is just as important as only response. Fol-
low-up data show very clearly that non-remitters have a
much higher risk of relapse/recurrence or even chronicity
than remitters. The problems of under-diagnosis and
under-treatment of depression also need to be addressed.
As for the near future, there is great hope that new mech-
anisms of action can overcome the limitations of the tra-
ditional and current antidepressant medications.
Unfortunately, some of the recent developments that
raised the most interest either turned out to be less effec-
tive than hoped, such as the substance P antagonists, or
did not yet lead to a drug likely to be marketed in the near
future, such as CRF antagonists, for example. On the other
hand the first melatonergic antidepressant, agomelatine,
is a successful new development. Agomelatine is a mela-
tonergic MT1 and MT2 receptor agonist with 5-HT2C
receptor antagonistic properties, and has shown antide-
pressant efficacy and favourable tolerability in several
clinical trials on patients with major depression.
Drug development is evolving fast and is aided by
improved brain imaging techniques, better animal mod-
els, and an increased knowledge of genetic markers.
Hopefully this will result in a change in the pharmaco-
therapy of depression and psychiatric diseases in general,
not on short term, but certainly in the next 50 years.
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